Citius Pharmaceuticals reports positive Phase 1 topline results for LYMPHIR/pembrolizumab combo in gynecologic cancers

Citius Pharmaceuticals, Inc.

Phase 1 trial of LYMPHIR plus KEYTRUDA in 25 evaluable patients with relapsed/refractory gynecologic cancers showed 24% objective response rate and 48% clinical benefit rate.
No unexpected safety signals or serious immune-related adverse events were observed at any dose level in the University of Pittsburgh-led study.
Full safety and efficacy results expected to be presented at an international cancer conference later this year.
Study investigators highlight potential for LYMPHIR to augment immune checkpoint inhibitor efficacy in ovarian cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.